Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC45H49N11O7 |
InChIKeyNQUBBBPLONXGFF-UHFFFAOYSA-N |
CAS Registry2093386-61-7 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 24 Mar 2017 |





